Centessa Pharmaceuticals plc – NASDAQ:CNTA
Centessa Pharmaceuticals stock price today
$17.68
+0.73
+4.31%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Centessa Pharmaceuticals stock price monthly change
+71.91%
month
Centessa Pharmaceuticals stock price quarterly change
+71.91%
quarter
Centessa Pharmaceuticals stock price yearly change
+112.14%
year
Centessa Pharmaceuticals key metrics
Market Cap | 2.19B |
Enterprise value | 31.07M |
P/E | -1.64 |
EV/Sales | N/A |
EV/EBITDA | -0.09 |
Price/Sales | N/A |
Price/Book | 1.05 |
PEG ratio | -0.03 |
EPS | -1.42 |
Revenue | N/A |
EBITDA | -156.01M |
Income | -138.71M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCentessa Pharmaceuticals stock price history
Centessa Pharmaceuticals stock forecast
Centessa Pharmaceuticals financial statements
Average Price Target
$21.6
Potential upside: 22.17%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -24.88M | |
|---|---|---|---|
| Sep 2023 | 0 | -38.64M | |
| Dec 2023 | 6.91M | -37.15M | -537.53% |
| Mar 2024 | 0 | -38.02M |
| 2023-11-13 | -0.46 | -0.4 |
|---|---|---|
| 2024-03-28 | -0.44 | -0.38 |
| 2024-05-13 | -0.41 | -0.38 |
| Jun 2023 | 392921000 | 116.31M | 29.6% |
|---|---|---|---|
| Sep 2023 | 377364000 | 117.97M | 31.26% |
| Dec 2023 | 362969000 | 126.72M | 34.91% |
| Mar 2024 | 328171000 | 113.00M | 34.44% |
| Jun 2023 | -44.06M | -71.09M | 12K |
|---|---|---|---|
| Sep 2023 | -37.39M | 48.70M | 14.74M |
| Dec 2023 | -31.10M | -18.28M | 6.37M |
| Mar 2024 | -37.26M | 16.75M | 10.48M |
Centessa Pharmaceuticals alternative data
| Aug 2023 | 82 |
|---|---|
| Sep 2023 | 64 |
| Oct 2023 | 64 |
| Nov 2023 | 64 |
| Dec 2023 | 75 |
| Jan 2024 | 75 |
| Feb 2024 | 75 |
| Mar 2024 | 75 |
| Apr 2024 | 75 |
| May 2024 | 76 |
| Jun 2024 | 77 |
| Jul 2024 | 77 |
Centessa Pharmaceuticals other data
33.22%
-34.56%
of CNTA is owned by hedge funds
26
-16
31.02M
-32.90M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 4267 |
| Mar 2024 | 0 | 51160 |
| Aug 2024 | 0 | 85000 |
| Sep 2024 | 0 | 301619 |
| Oct 2024 | 0 | 66742 |
| Nov 2024 | 0 | 102504 |
| Dec 2024 | 0 | 274125 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | WEINHOFF GREGORY M officer: Chief Business Officer | Ordinary Shares | 10,000 | $3.85 | $38,500 | ||
Sale | WEINHOFF GREGORY M officer: Chief Business Officer | Ordinary Shares | 10,000 | $17.04 | $170,400 | ||
Option | WEINHOFF GREGORY M officer: Chief Business Officer | Share Option (right to buy) | 10,000 | $3.85 | $38,500 | ||
Sale | SAHA SAURABH director, officer: Chief Execut.. | Ordinary Shares | 55,000 | $17.44 | $959,035 | ||
Sale | ANDERSON KAREN M. officer: Chief Pe.. | Ordinary Shares | 10,624 | $17.32 | $184,040 | ||
Option | BUSH TIA L officer: Chief Technology & Qua.. | Ordinary Shares | 17,813 | $3.85 | $68,580 | ||
Sale | BUSH TIA L officer: Chief Technology & Qua.. | Ordinary Shares | 17,813 | $18 | $320,634 | ||
Option | BUSH TIA L officer: Chief Technology & Qua.. | Share Option (right to buy) | 17,813 | $3.85 | $68,580 | ||
Option | ANDERSON KAREN M. officer: Chief Pe.. | Ordinary Shares | 10,624 | $3.85 | $40,902 | ||
Option | ANDERSON KAREN M. officer: Chief Pe.. | Share Option (right to buy) | 10,624 | $3.85 | $40,902 |
-
What's the price of Centessa Pharmaceuticals stock today?
One share of Centessa Pharmaceuticals stock can currently be purchased for approximately $17.68.
-
When is Centessa Pharmaceuticals's next earnings date?
Unfortunately, Centessa Pharmaceuticals's (CNTA) next earnings date is currently unknown.
-
Does Centessa Pharmaceuticals pay dividends?
No, Centessa Pharmaceuticals does not pay dividends.
-
How much money does Centessa Pharmaceuticals make?
Centessa Pharmaceuticals has a market capitalization of 2.19B. Centessa Pharmaceuticals made a loss 151.09M US dollars in net income (profit) last year or -$0.38 on an earnings per share basis.
-
What is Centessa Pharmaceuticals's stock symbol?
Centessa Pharmaceuticals plc is traded on the NASDAQ under the ticker symbol "CNTA".
-
What is Centessa Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Centessa Pharmaceuticals?
Shares of Centessa Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Centessa Pharmaceuticals have?
As Jul 2024, Centessa Pharmaceuticals employs 77 workers, which is 3% more then previous quarter.
-
When Centessa Pharmaceuticals went public?
Centessa Pharmaceuticals plc is publicly traded company for more then 4 years since IPO on 28 May 2021.
-
What is Centessa Pharmaceuticals's official website?
The official website for Centessa Pharmaceuticals is centessa.com.
-
How can i contact Centessa Pharmaceuticals?
Centessa Pharmaceuticals can be reached via phone at +44 20 3920 6789.
-
What is Centessa Pharmaceuticals stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Centessa Pharmaceuticals in the last 12 months, the avarage price target is $21.6. The average price target represents a 22.17% change from the last price of $17.68.
Centessa Pharmaceuticals company profile:
Centessa Pharmaceuticals plc
centessa.comExchange:
NASDAQ
Full time employees:
76
Industry:
Biotechnology
Sector:
Healthcare
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
1 Ashley Road
Altrincham, WA14 2DT
Altrincham, WA14 2DT
CIK: 0001847903
ISIN: US1523091007
CUSIP: 152309100
